Selected research
Industry Research
Mesenchymal Stem Cell Drugs Industry Research Report 2026
Market perspective
The global Mesenchymal Stem Cell Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Mesenchymal Stem Cell Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Mesenchymal Stem Cell Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Mesenchymal Stem Cell Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Mesenchymal Stem Cell Drugs include Anterogen, JCR Pharmaceuticals, Medipost, Pharmicell, Stempeutics, Osiris Therapeutics, CHIESI Farmaceutici and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Mesenchymal Stem Cell Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mesenchymal Stem Cell Drugs Market by Company
Anterogen
JCR Pharmaceuticals
Medipost
Pharmicell
Stempeutics
Osiris Therapeutics
CHIESI Farmaceutici
Takeda
Mesenchymal Stem Cell Drugs Segment by Type
Autologous Source
Allogeneic Source
Mesenchymal Stem Cell Drugs Segment by Application
Tissue Repair
Immunomodulation
Mesenchymal Stem Cell Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mesenchymal Stem Cell Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mesenchymal Stem Cell Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mesenchymal Stem Cell Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mesenchymal Stem Cell Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mesenchymal Stem Cell Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mesenchymal Stem Cell Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Autologous Source
- Allogeneic Source
Applications
- Tissue Repair
- Immunomodulation
Companies covered
- Anterogen
- JCR Pharmaceuticals
- Medipost
- Pharmicell
- Stempeutics
- Osiris Therapeutics
- CHIESI Farmaceutici
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Mesenchymal Stem Cell Drugs Market Size (2021-2032)
- 2.2.2 Global Mesenchymal Stem Cell Drugs Sales (2021-2032)
- 2.2.3 Global Mesenchymal Stem Cell Drugs Market Average Price (2021-2032)
- 2.3 Mesenchymal Stem Cell Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Autologous Source
- 2.3.3 Allogeneic Source
- 2.4 Mesenchymal Stem Cell Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Tissue Repair
- 2.4.3 Immunomodulation
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mesenchymal Stem Cell Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Mesenchymal Stem Cell Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Mesenchymal Stem Cell Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Mesenchymal Stem Cell Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Mesenchymal Stem Cell Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Mesenchymal Stem Cell Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Mesenchymal Stem Cell Drugs, Product Type & Application
- 3.8 Global Manufacturers of Mesenchymal Stem Cell Drugs, Established Date
- 3.9 Global Mesenchymal Stem Cell Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Anterogen
- 4.1.1 Anterogen Company Information
- 4.1.2 Anterogen Business Overview
- 4.1.3 Anterogen Mesenchymal Stem Cell Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Anterogen Mesenchymal Stem Cell Drugs Product Portfolio
- 4.1.5 Anterogen Recent Developments
- 4.2 JCR Pharmaceuticals
- 4.2.1 JCR Pharmaceuticals Company Information
- 4.2.2 JCR Pharmaceuticals Business Overview
- 4.2.3 JCR Pharmaceuticals Mesenchymal Stem Cell Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 JCR Pharmaceuticals Mesenchymal Stem Cell Drugs Product Portfolio
- 4.2.5 JCR Pharmaceuticals Recent Developments
- 4.3 Medipost
- 4.3.1 Medipost Company Information
- 4.3.2 Medipost Business Overview
- 4.3.3 Medipost Mesenchymal Stem Cell Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Medipost Mesenchymal Stem Cell Drugs Product Portfolio
- 4.3.5 Medipost Recent Developments
- 4.4 Pharmicell
- 4.4.1 Pharmicell Company Information
- 4.4.2 Pharmicell Business Overview
- 4.4.3 Pharmicell Mesenchymal Stem Cell Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pharmicell Mesenchymal Stem Cell Drugs Product Portfolio
- 4.4.5 Pharmicell Recent Developments
- 4.5 Stempeutics
- 4.5.1 Stempeutics Company Information
- 4.5.2 Stempeutics Business Overview
- 4.5.3 Stempeutics Mesenchymal Stem Cell Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Stempeutics Mesenchymal Stem Cell Drugs Product Portfolio
- 4.5.5 Stempeutics Recent Developments
- 4.6 Osiris Therapeutics
- 4.6.1 Osiris Therapeutics Company Information
- 4.6.2 Osiris Therapeutics Business Overview
- 4.6.3 Osiris Therapeutics Mesenchymal Stem Cell Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Osiris Therapeutics Mesenchymal Stem Cell Drugs Product Portfolio
- 4.6.5 Osiris Therapeutics Recent Developments
- 4.7 CHIESI Farmaceutici
- 4.7.1 CHIESI Farmaceutici Company Information
- 4.7.2 CHIESI Farmaceutici Business Overview
- 4.7.3 CHIESI Farmaceutici Mesenchymal Stem Cell Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 CHIESI Farmaceutici Mesenchymal Stem Cell Drugs Product Portfolio
- 4.7.5 CHIESI Farmaceutici Recent Developments
- 4.8 Takeda
- 4.8.1 Takeda Company Information
- 4.8.2 Takeda Business Overview
- 4.8.3 Takeda Mesenchymal Stem Cell Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Takeda Mesenchymal Stem Cell Drugs Product Portfolio
- 4.8.5 Takeda Recent Developments
5 Global Mesenchymal Stem Cell Drugs Market Scenario by Region
- 5.1 Global Mesenchymal Stem Cell Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mesenchymal Stem Cell Drugs Sales by Region: 2021-2032
- 5.2.1 Global Mesenchymal Stem Cell Drugs Sales by Region: 2021-2026
- 5.2.2 Global Mesenchymal Stem Cell Drugs Sales by Region: 2027-2032
- 5.3 Global Mesenchymal Stem Cell Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Mesenchymal Stem Cell Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Mesenchymal Stem Cell Drugs Revenue by Region: 2027-2032
- 5.4 North America Mesenchymal Stem Cell Drugs Market Facts & Figures by Country
- 5.4.1 North America Mesenchymal Stem Cell Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Mesenchymal Stem Cell Drugs Sales by Country (2021-2032)
- 5.4.3 North America Mesenchymal Stem Cell Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Mesenchymal Stem Cell Drugs Market Facts & Figures by Country
- 5.5.1 Europe Mesenchymal Stem Cell Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Mesenchymal Stem Cell Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Mesenchymal Stem Cell Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Mesenchymal Stem Cell Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Mesenchymal Stem Cell Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Mesenchymal Stem Cell Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Mesenchymal Stem Cell Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Mesenchymal Stem Cell Drugs Market Facts & Figures by Country
- 5.7.1 South America Mesenchymal Stem Cell Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Mesenchymal Stem Cell Drugs Sales by Country (2021-2032)
- 5.7.3 South America Mesenchymal Stem Cell Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Mesenchymal Stem Cell Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Mesenchymal Stem Cell Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Mesenchymal Stem Cell Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Mesenchymal Stem Cell Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Mesenchymal Stem Cell Drugs Sales by Type (2021-2032)
- 6.1.1 Global Mesenchymal Stem Cell Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Mesenchymal Stem Cell Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Mesenchymal Stem Cell Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Mesenchymal Stem Cell Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Mesenchymal Stem Cell Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Mesenchymal Stem Cell Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Mesenchymal Stem Cell Drugs Sales by Application (2021-2032)
- 7.1.1 Global Mesenchymal Stem Cell Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Mesenchymal Stem Cell Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Mesenchymal Stem Cell Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Mesenchymal Stem Cell Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Mesenchymal Stem Cell Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Mesenchymal Stem Cell Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Mesenchymal Stem Cell Drugs Value Chain Analysis
- 8.1.1 Mesenchymal Stem Cell Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Mesenchymal Stem Cell Drugs Production Mode & Process
- 8.2 Mesenchymal Stem Cell Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Mesenchymal Stem Cell Drugs Distributors
- 8.2.3 Mesenchymal Stem Cell Drugs Customers
9 Global Mesenchymal Stem Cell Drugs Analyzing Market Dynamics
- 9.1 Mesenchymal Stem Cell Drugs Industry Trends
- 9.2 Mesenchymal Stem Cell Drugs Industry Drivers
- 9.3 Mesenchymal Stem Cell Drugs Industry Opportunities and Challenges
- 9.4 Mesenchymal Stem Cell Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst